Charlotte's Web Holdings (CWBHF) Net Income towards Common Stockholders (2021 - 2026)
Charlotte's Web Holdings (CWBHF) posted quarterly Net Income towards Common Stockholders of -$13.1 million for Q1 2026, down 111.08% year-over-year from $118.4 million in Q1 2025, and down 14.79% quarter-over-quarter from -$11.4 million in Q4 2025.
Charlotte's Web Holdings (CWBHF) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Charlotte's Web Holdings (CWBHF) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$13.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 111.08% year-over-year to -$13.1 million; the TTM figure through Mar 2026 stood at -$36.6 million (down 38.67% YoY), while the FY2025 annual figure was -$29.7 million, changed 0.35% from the prior year.
- Net Income towards Common Stockholders eased to -$13.1 million in Q1 2026 per CWBHF's latest filing, from -$11.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $2.8 million in Q2 2023 and bottomed at -$35.2 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$9.2 million across 5 years, with a median of -$7.9 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders sank 876.58% — and 2023, when it surged 136.14%.
- Charlotte's Web Holdings' Net Income towards Common Stockholders stood at -$35.2 million in 2022, then surged by 75.63% to -$8.6 million in 2023, then jumped by 60.77% to -$3.4 million in 2024, then plunged by 239.16% to -$11.4 million in 2025, then decreased by 14.79% to -$13.1 million in 2026.
- Business Quant data shows CWBHF's Net Income towards Common Stockholders at -$13.1 million in Q1 2026, -$11.4 million in Q4 2025, and -$5.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Charlotte's Web Holdings | 62.78 Mn | 48.79 Mn | 5.16 Mn | -4.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.13 Mn |
| Mar 31, 2026 | -13.11 Mn |
| Dec 31, 2025 | -11.42 Mn |
| Sep 30, 2025 | -5.82 Mn |
| Jun 30, 2025 | -6.29 Mn |
| Mar 31, 2025 | -6.21 Mn |
| Dec 31, 2024 | -3.37 Mn |
| Sep 30, 2024 | -5.79 Mn |
| Jun 30, 2024 | -11.06 Mn |
| Mar 31, 2024 | -9.63 Mn |
| Dec 31, 2023 | -8.59 Mn |
| Sep 30, 2023 | -15.14 Mn |
| Jun 30, 2023 | 2.84 Mn |
| Mar 31, 2023 | -2.91 Mn |
| Dec 31, 2022 | -35.23 Mn |
| Sep 30, 2022 | -7.59 Mn |
| Jun 30, 2022 | -7.87 Mn |
| Mar 31, 2022 | -8.63 Mn |
| Dec 31, 2021 | -118.25 Mn |
| Sep 30, 2021 | -777,000.00 |